A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer

European Journal of Cancer

Volumn 34, Issue 7, 1998, Pages 1008-1014

  Gluck S ^a   Germond, C ^a   Lopez, P ^a   Cano, P ^a   Dorreen, M ^a   Koski, T ^a   Arnold, A ^b   Dulude, H ^c   Gallant, G ^c  

^a Northeastern Ontario Regional Cancer Centre   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c Bristol Myers Squibb Canada   (Canada)

Author keywords

ABSC; Breast cancer; Combination chemotherapy; Metastatic; Paclitaxel; Phase I; Taxoid

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; MESNA; MITOXANTRONE; PACLITAXEL;

ADULT; ARTICLE; BRADYCARDIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIAPHORESIS; DIARRHEA; DOSE RESPONSE; DRUG MEGADOSE; ERYTHROCYTE CONCENTRATE; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM PERMISSIBLE DOSE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; MITOXANTRONE; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032103859     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10168-X     Document Type: Article

References (39)

1. National Cancer Institute of Canada; Statistics Canada; Provincial Cancer Registries; Health Canada. Canadian Cancer Statistics 1995. ISSN 0835-2976, January 1995.
2. Clavel K., Catimel G. Breast cancer: chemotherapy in the treatment of advanced disease. Eur J Cancer. 29A:1993;598-604.
3. Sledge G.W., Antman K.H. Progress in chemotherapy for metastatic breast cancer. Semin Oncol. 19:1992;317-332.
4. Ross MB, Buzdar AU, Smith TL, et al. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy, comparison of consecutive series of patients in 1950s, 1960s, and 1970s. Cancer 1985, 55, 341-346.
5. Falkson G., Gelman R.S., Leone L., Falkson C.I. Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of eastern cooperative group and cancer and leukemia group B studies. Cancer. 66:1990;1621-1629.
6. The Ontario Cancer Treatment and Research Foundation. Cancer in Ontario 1994-1995. D. Blackstone and K. Kwiatkowska, OCTRF, Toronto.
7. Antman K, Corringham R, Devries E, et al. Dose intensive therapy in breast cancer. Bone Marrow Transplant 1992, 10, 67-73.
8. Osborne C.K. Dose-intensity as a therapeutic strategy in breast cancer. Breast Cancer Res Treat. 20:1991;11-14.
9. Kessinger A, Armitage JO. The use of peripheral stem cell support of high-dose chemotherapy. In DeVita VT, Hellman S, Rosenberg RA, eds. Important Advances in Oncology 1993. Philadelphia, J. B. Lippincott, 1993, 167-175.
10. Glück S., Ho A.D. High-dose chemotherapy (HDCT) with autologous blood cell (BC) support in metastatic breast cancer (MBC). Eur J Cancer. 32A:(2):1996;35.
11. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992, 10, 102-110.
12. Ayash LJ, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994, 12, 37-44.
13. Ghalie R, Richman CM, Adler SS, et al. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol 1994, 12, 342-346.
14. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993, 11, 1132-1143.
15. Somlo GS, Doroshow JH, Forman SJ, et al. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer 1994, 73, 125-134.
16. Dunphy FR, Spitzer G, Buzdar AU, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990, 8, 1207-1216.
17. Sphall EJ, Jones RB, Bearman SI, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994, 12, 28-36.
18. Kennedy M.J., Beveridge R.A., Rowley S.D., Gordon G.B., Abeloff M.D., Davidson N.E. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. Natl Cancer Inst. 83:1991;920-926.
19. Williams S.F., Gilewski T., Mick R., Bitran J.D. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol. 10:1992;1743-1747.
20. Mulder NH, Mulder POM, Sleijfer D Th, et al. Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer. Eur J Cancer 1993, 29A, 668-671.
21. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997, 115, 1870-1879.
22. Taxol. Lancet 1992, 339, 1447-1448.
23. Bissett D., Kaye S.R. Taxol and taxotere-current status and future prospects. Eur J Cancer. 29A:(9):1993;1228-1231.
24. Rowinsky E.K., Onetto N., Canetta R.M., Arbuck S. Taxol: the first of the taxanes, an important new class of antitumour agents. Semin Oncol. 19:(6):1992;646-662.
25. ®) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol 1993, 20(4), 40-45.
26. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991, 83, 1797-1805.
27. Stemmer SM, Cagnoni PJ, Shpall EJ, et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous haematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 1996, 14(5), 1463-1472.
28. ®, TXL) with 5 different cytotoxic drugs: effect on three different cell lines. Proc AACR 1994, 35, 335 (#1992).
29. ®, TXL) with different cytotoxic drugs: effect on malignant cell lines in vitro. Can J Infect Dis 1995, (6), 397C:#3041.
30. Glück S, DesRochers S, Cano C, et al. High-dose chemotherapy followed by autologous blood cell transplantation: a safe and effective outpatient approach. Bone Marrow Transplant 1997, 6, 431-435.
31. Hayward J.L., Carbone P.P., Heuson J-C., Kumaoka S., Segaloff A., Rubens R.D. Assessment of response to therapy in advanced breast cancer. Cancer. 39:1997;1289-1294.
32. Ho AD, Glück S, Germond C, et al. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 1993, 7, 1738-1746.
33. Glück S, Porter K, Chadderton T, Dietz G, Germond C. Depletion of DMSO (dimethylsulfoxide) prior to autografting after high-dose chemotherapy for metastatic breast cancer. Blood 1993, 82, 430a:#1705.
34. Glück S., Gagnon A. Neutropenic fever in patients after high-dose chemotherapy followed by autologous transplantation and GM-CSF. Bone Marrow Transplant. 14:1994;989-990.
35. Miller A.B., Hoogstraten B., Staguet M., Winkler A. Reporting results of cancer treatment. Cancer. 49:1981;207-214.
36. Schiller JH, Storer B, Tutsch K, et al. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. Semin Oncol 1994, 21(5), 9-15.
37. Fields K, Perkins J, Elfenbeing G. et al. A phase I dose escalation trial of high dose Taxol, Novantrone, and thiotepa (TNT) followed by autologous stem cell rescue (ASCR): toxicity. Proc ASCO 1995, 14, A953.
38. Crown J, Fennelly D, Schneider J, et al. Escalating dose Taxol (T)+high-dose (HD) cyclophosphamide (C)/G-CSF (G) as induction and to mobilize peripheral blood progenitors (PBP) for use as rescue following multiple course of HD carboplatin (P)/C: a phase I trial in ovarian cancer patients (pts). Proc ASCO 1994, 13, A831.
39. Vermorken JB, Bokkel Huinink WW ten, Mandjes IA. et al. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. Semin Oncol 1995, 22, 16-22.